PubRank

John B Haanen

Author PubWeight™ 143.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 45.46
3 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 14.71
4 Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013 5.36
5 Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013 5.23
6 Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009 2.57
7 Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009 1.60
8 Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2010 1.57
9 Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol 2012 1.41
10 Targeted therapy for renal cell cancer: current perspectives. Discov Med 2010 1.18
11 Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother 2011 1.14
12 Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008 1.11
13 Behavior and function of tissue-resident memory T cells. Adv Immunol 2012 1.03
14 Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer 2013 0.84
15 Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Int J Cancer 2011 0.82
16 RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother 2010 0.81
17 Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology 2016 0.80
18 Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther 2012 0.79
19 Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011 0.78